SYNTHETIC IGE PEPTIDE VACCINE FOR IMMUNOTHERAPY OF ALLERGY

用于过敏免疫治疗的合成 IGE 肽疫苗

• 批准号: 7349812
• 负责人: KRISHNA H MURTHY
• 金额: $ 3.39万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349812
• 关键词: SYNTHETIC; IGE; PEPTIDE; VACCINE; IMMUNOTHERAPY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The experiment will examine the efficacy of UBI¿s therapy for allergy in a relevant animal model (baboons). The UBI allergy therapeutic contains a piece of Immunoglobulin E (IgE) antibody. [IgE antibodies are the antibodies that react against allergens and cause most allergic reactions.] The piece of IgE in the UBI therapy was produced by chemical synthesis and has been combined with various vaccine components. Therefore the UBI therapy has been designed to act as a vaccine that elicits protective antibodies against the individual¿s own IgE. Accordingly, the vaccine will neutralize the ability of any IgE to cause allergic reactions. This therapeutic anti-IgE immune response is specifically directed against only the targeted piece of IgE, while having no effect on normal antibodies. This IgE vaccine approach to allergy therapy has the additional advantage that it will be effective therapy for all IgE-mediated allergies with no need to identify or tailor treatment for specific allergens such as tree and grass pollens, animal danders, dust mites, etc.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该实验将在相关动物模型（狒狒）中检查UBI治疗过敏症的疗效。UBI过敏治疗剂含有一片免疫球蛋白E（IgE）抗体。[IgE抗体是对过敏原起反应并引起大多数过敏反应的抗体。UBI疗法中的IgE片段是通过化学合成产生的，并已与各种疫苗成分结合。因此，UBI疗法被设计成一种疫苗，可以激发针对个体自身IgE的保护性抗体。因此，疫苗将中和任何IgE引起过敏反应的能力。这种治疗性抗IgE免疫应答仅特异性针对IgE的靶向片段，而对正常抗体没有影响。这种过敏治疗的IgE疫苗方法具有额外的优点，即它将是所有IgE介导的过敏的有效治疗，而不需要鉴定或定制针对特定过敏原如树木和草花粉、动物皮屑、尘螨等的治疗。